Puma Biotechnology Inc (NASDAQ:PBYI) insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Puma Biotechnology Inc (NASDAQ PBYI) traded down $4.40 during trading on Wednesday, reaching $93.85. The company’s stock had a trading volume of 908,500 shares, compared to its average volume of 1,093,497. Puma Biotechnology Inc has a 1-year low of $28.35 and a 1-year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company earned ($1.11) earnings per share. sell-side analysts forecast that Puma Biotechnology Inc will post -8.19 earnings per share for the current year.

Several equities research analysts have commented on PBYI shares. Bank of America restated a “buy” rating and issued a $135.00 price objective (up previously from $117.00) on shares of Puma Biotechnology in a research report on Monday, October 9th. Citigroup restated a “buy” rating and issued a $156.00 price objective (up previously from $114.00) on shares of Puma Biotechnology in a research report on Thursday, October 5th. J P Morgan Chase & Co restated a “buy” rating and issued a $131.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Stifel Nicolaus restated a “buy” rating and issued a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. Finally, BidaskClub lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $130.67.

Several hedge funds have recently made changes to their positions in the company. Bank of Montreal Can raised its stake in shares of Puma Biotechnology by 1.8% during the 2nd quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 97 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 140 shares during the period. Legal & General Group Plc raised its stake in shares of Puma Biotechnology by 2.8% during the 1st quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 249 shares during the period. Rhumbline Advisers raised its stake in shares of Puma Biotechnology by 0.8% during the 2nd quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock worth $2,948,000 after buying an additional 271 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Puma Biotechnology by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock worth $1,950,000 after buying an additional 437 shares during the period. 96.05% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (PBYI) Insider Charles R. Eyler Sells 1,322 Shares” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://theolympiareport.com/2017/12/06/puma-biotechnology-inc-pbyi-insider-charles-r-eyler-sells-1322-shares.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.